Minor P D, Evans D M, Ferguson M, Schild G C, Westrop G, Almond J W
J Gen Virol. 1985 May;66 ( Pt 5):1159-65. doi: 10.1099/0022-1317-66-5-1159.
The characterization of over 300 mutants, derived from two strains of poliovirus type 3 and selected for resistance to neutralization by monoclonal antibodies, has led to the further definition of the major antigenic site involved in neutralization. The site encompasses amino acids 89 to 100 of VP1. A subsidiary antigenic site near the C-terminus of VP1 has been identified for the Sabin vaccine strain of poliovirus type 3. Of 59 monoclonal antibodies to poliovirus type 3 examined, 27 had virus-neutralizing activity and 25 of these were identified as directed against the major site on VP1 (designated site 1), indicating the immunodominant role of this site. One of the six monoclonal antibodies that recognized the subsidiary antigenic site on VP1 (designated site 2) possessed virus-neutralizing activity. The identification of the principal antigenic site of the virus provides a rational basis for attempts at the development of synthetic oligopeptide vaccines against poliovirus type 3.
对来自两株3型脊髓灰质炎病毒、经筛选对单克隆抗体中和作用具有抗性的300多个突变体进行的特性分析，进一步明确了参与中和作用的主要抗原位点。该位点包含VP1的第89至100位氨基酸。已为3型脊髓灰质炎病毒的萨宾疫苗株确定了一个位于VP1 C末端附近的次要抗原位点。在检测的59种针对3型脊髓灰质炎病毒的单克隆抗体中，27种具有病毒中和活性，其中25种被确定为针对VP1上的主要位点（称为位点1），表明该位点具有免疫主导作用。识别VP1上次要抗原位点（称为位点2）的六种单克隆抗体之一具有病毒中和活性。病毒主要抗原位点的确定为开发针对3型脊髓灰质炎病毒的合成寡肽疫苗的尝试提供了合理依据。
